Announced details
Drug discovery research in the renal field; target molecule identification for specified diseases
DDAIF has been adopted by multiple major pharmaceutical companies and has built a track record. The specific number of companies and cases is not disclosed.
A business and collaboration relationship involving a co-creation project to identify drug discovery targets in the renal field. Capital and personnel relationships are not disclosed.
Head office: Tokyo. A total healthcare company operating medical-related and nutraceuticals-related businesses. Other details are not disclosed.
DDAIF-related technology has secured a total of 21 patent rights in Japan, Europe, the United States and South Korea. Individual patent numbers and expiration dates are not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, KIBIT |
| Counterparty | Otsuka Pharmaceutical Co., Ltd. |
| Counterparty overview | Head office: Tokyo. A total healthcare company operating medical-related and nutraceuticals-related businesses. Other details are not disclosed. |
| Relationship with the Company | A business and collaboration relationship involving a co-creation project to identify drug discovery targets in the renal field. Capital and personnel relationships are not disclosed. |
| Launch date | 27 October 2026 (announced that the project had begun; the project's actual start date is not disclosed) |
| Applicable area | Drug discovery research in the renal field; target molecule identification for specified diseases |
| Registration number and expiry date | DDAIF-related technology has secured a total of 21 patent rights in Japan, Europe, the United States and South Korea. Individual patent numbers and expiration dates are not disclosed. |
| Usage history | DDAIF has been adopted by multiple major pharmaceutical companies and has built a track record. The specific number of companies and cases is not disclosed. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The project combines Otsuka Pharmaceutical's drug discovery research expertise with FRONTEO's AI analytical technology and the expertise of its drug discovery researchers to identify highly novel target molecule candidates in the renal field and support the creation of innovative therapeutics.